Michael Mark Millenson
Sidney Kimmel Cancer Center · 112 works · 9,321 citations · h-index 33
Top works
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- Venous Thromboembolic Disease
- NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018
- Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
- Cancer-Associated Venous Thromboembolic Disease, Version 1.2015
- Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database
- Acute Myeloid Leukemia, Version 2.2013
- Cancer- and Chemotherapy-Induced Anemia
- Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network
- Cancer- and Treatment-Related Anemia Clinical Practice Guidelines in Oncology
- Venous Thromboembolic Disease
- Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies
- Lack of benefit of central nervous system prophylaxis for diffuse large B‐cell lymphoma in the rituximab era
- Acute Myeloid Leukemia
- Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database
- Routine mammography is associated with earlier stage disease and greater eligibility for breast conservation in breast carcinoma patients age 40 years and older